Doses - BUSULFAN
Small Animals:
For chronic granulocytic leukemias (not during "blastic" phase¯of no benefit): 3 -4mg/m2 PO once daily. Discontinue when total white blood cell count reaches approximately 15, 000. Repeat as necessary. May require up to two weeks to observe a positive response. If there is too rapid a decline in total WBC's, discontinue drug. (Jacobs,
Lumsden et al. 1992)
Monitoring Parameters - 1) CBC; 2) Serum uric acid; 3) Efficacy
Client Information - Clients must understand the importance of both administering busulfan asdirected and to report immediately any signs associated with toxicity (e.g., abnormal bleeding, bruising, urination, depression, infection, shortness of breath, etc.).
Dosage Forms/Preparations/FDA Approval Status/Withholding Times - Veterinary-Approved Products: None
For chronic granulocytic leukemias (not during "blastic" phase¯of no benefit): 3 -4mg/m2 PO once daily. Discontinue when total white blood cell count reaches approximately 15, 000. Repeat as necessary. May require up to two weeks to observe a positive response. If there is too rapid a decline in total WBC's, discontinue drug. (Jacobs,
Lumsden et al. 1992)
Monitoring Parameters - 1) CBC; 2) Serum uric acid; 3) Efficacy
Client Information - Clients must understand the importance of both administering busulfan asdirected and to report immediately any signs associated with toxicity (e.g., abnormal bleeding, bruising, urination, depression, infection, shortness of breath, etc.).
Dosage Forms/Preparations/FDA Approval Status/Withholding Times - Veterinary-Approved Products: None